Coverage
-
December 09, 2016
The U.S. Federal Trade Commission asked a D.C. federal court Friday not to allow Boehringer Ingelheim Pharmaceuticals to delay producing documents related to a pay-for-delay suit over stroke prevention drug Aggrenox while the company appeals a decision on whether the documents are protected.
4 other articles on this case.
View all »